Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$13.44 USD
-0.39 (-2.82%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $13.43 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Denali Therapeutics Inc. has a market cap of $2.01B, which represents its share price of $13.83 multiplied by its outstanding shares number of 145.28M. As a mid-cap company, DNLI's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
DNLI 13.44 -0.39(-2.82%)
Will DNLI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DNLI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNLI
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review
DNLI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?
Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Other News for DNLI
Denali Therapeutics' CMO Joins Royalty Pharma Board | DNLI Stock News
Royalty Pharma appoints Ho, Weatherman to board of directors
Denali noted no FDA panel meeting in call with William Blair
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License ...
Denali Therapeutics Inc (DNLI) Announces FDA Priority Review for Tividenofusp Alfa | DNLI stock news